News Articles and Montana BioScience Alliance Newsletters
The University of Montana in Missoula and Montana State University in Bozeman have achieved “R1” designations for their research programs. The “R1” classification is conferred by the Carnegie Classification of Institutions of Higher Education organization based on factors including research expenditures, staffing, and number of doctorates awarded.
Montana State University Billings announces the launch of the Institute for Neurodiversity and Applied Behavior Analysis at the Montana Center for Inclusive Education (MCIE) on university campus. The Institute will serve children in the region with mental, social, and behavioral differences associated with autism spectrum disorders, developmental disabilities, similar mental health disorders, and other behavioral disabilities, by providing direct and telehealth clinical support.
BioScience Laboratories, a Nelson Labs company located in Bozeman, MT, and a leader in topical antimicrobial-product testing in the consumer, pharmaceutical, and medical-device industries, operates a biosafety-level-3 (BSL-3) laboratory that was inspected by the Centers for Disease Control and Prevention (CDC) last year. The CDC has since confirmed that the Bozeman facility’s BSL-3 lab and related procedures adequately meet guidelines for the company to test all common and concerning strains of SARS-CoV-2 and other potentially dangerous pathogens.
Last year, the World Trade Organization (WTO) proposed that biotechnology companies, including some in Montana, be required to give their formulas for COVID-19 vaccines to countries that aren’t as advanced as the U.S. in developing these technologies. The Biden administration has supported this proposal, but we have deep concerns about it.
The immuno-oncology market has grown at a compound rate of 10%, from $57 billion to $69 billion in 2021. It is expected to reach around $98 billion by 2025. This is a highly competitive market, so companies in this sector have to innovate rapidly by creating novel drugs and therapies. Montana’s Inimmune recently made the top-20 list.
Thirty regional companies will be selected to present at the Rocky Mountain Life Sciences Investor & Partnering Conference. Companies seeking seed, early-stage, late-stage funding in the medical device, diagnostic, biotech, pharmaceutical, and digital health sectors are encouraged to apply.
With new labeling requirements, bioengineering entered consumer consciousness in a new way this year—but people are learning the benefits, according to Sarah Gallo, BIO’s VP of Agriculture and Environment, in this podcast.
From the NIne Questions for the World podcast, December 15, 2021. BIO President Michelle McMurray-Heath is interviewed by Richard Haass.